消息
Simpson Manufacturing Co., Inc. (NYSE:SSD) reported Q4 2025 revenue of $539.3 million, a 4.2 % year‑on‑year increase and a 1.6 % beat on analyst estimates. The quarter’s operating margin fell to 13.9 % from 15.0 % in Q4 2024, while adjusted EBITDA reached $104.7 million, exceeding analyst projections by 10.9 %. GAAP profit was $1.35 per share, 11.1...
11/02/2026 | Simpson Manufacturing Co., Inc.
Management highlighted the Goodyear Forward program, which delivered $1.5 billion of run‑rate benefits and is expected to contribute $100 million in Q1 and $300 million for the full year. CEO Mark Stewart announced a 10 % organic share‑of‑industry growth base case for 2026, underpinned by cost discipline, premium product mix and inventory managemen...
11/02/2026 | The Goodyear Tire & Rubber Company
The company’s debt profile remains heavy: net debt is about $6.5 billion against a market capitalization of roughly $3 billion, and its enterprise‑value‑to‑free‑cash‑flow ratio is 55×. Following the earnings release, the share price fell 13.5–15 % in morning trade.
11/02/2026 | The Goodyear Tire & Rubber Company
Segment results were mixed: the Americas operating income fell due to non‑recurrent insurance recoveries and the sale of the Chemical business, whereas the Europe, Middle East and Africa region saw a 4.9 % operating‑income rise thanks to favorable price‑mix and currency actions. Operating margin improved to 6.6 % from 5.3 % in Q4 2024, and the free...
11/02/2026 | The Goodyear Tire & Rubber Company
Goodyear reported fourth‑quarter 2025 revenue of $4.92 billion, a 0.6 % year‑over‑year decline but 1.3 % above analyst expectations. Adjusted earnings per share were $0.39 (or $0.36 GAAP), missing the consensus estimate of $0.45 (or $0.61) and leaving the EPS unchanged from the same period a year earlier. Net income for the quarter was $105 million...
11/02/2026 | The Goodyear Tire & Rubber Company
Benchmark’s new Buy rating focuses on the company’s ethanol segment, which is gaining momentum as agribusiness headwinds ease. The rating notes that ANDE’s long‑term growth plan targets earnings per share of US$7.00 by 2028, a 36 % compounded annual growth rate from 2026 onward. To support this trajectory, the firm is investing US$60 million in a c...
11/02/2026 | The Andersons, Inc.
The Andersons, Inc. (NASDAQ:ANDE) is currently trading at an all‑time high, yet a 2‑Stage Free Cash Flow to Equity model values the stock at US$58.70, below the market price of US$65.77. The model, using a 7.6% cost of equity, estimates the company’s total equity at US$2.0 billion, implying a fair P/E of 12.9. Analysts note that the Bloomberg‑style...
11/02/2026 | The Andersons, Inc.
BioGaia AB (publ) is a Swedish healthcare company focused on probiotic products for gut, oral, and immune health, with a market capitalization of approximately SEK 11.05 billion. Its 2023 revenue came largely from the Pediatrics segment, which generated SEK 1.09 billion. Despite a 6.2 % dip in earnings last year, the company projects an annual earn...
10/02/2026 | BioGaia AB (publ)
PSP Swiss Property (VTX:PSPN) is heavily weighted by institutional investors, who hold about 51% of the company’s shares, making the stock price sensitive to their trading actions. The largest institutional shareholder is UBS Asset Management AG with roughly 15% of outstanding shares. Insider ownership is minimal, at less than 1%, while the general...
10/02/2026 | PSP Swiss Property AG
Shield Therapeutics PLC (AIM:STX) saw its shares rise to 10.14p, a 5 % increase, after the U.S. FDA granted an additional three‑year extension of data exclusivity for its flagship product Accrufer. The new protection, effective until December 19 2028, augments existing patent coverage that extends into the mid‑2030s, thereby extending the company’s...
10/02/2026 | Shield Therapeutics plc